Hanson Pharmaceuticals announced on the Hong Kong Stock Exchange that the group's self-developed tyrosine kinase 2 selective allosteric inhibitor HS-10374 has reached common major endpoints in critical phase III clinical trials for moderate to severe plaque psoriasis in adults.

Zhitongcaijing · 1d ago
Hanson Pharmaceuticals announced on the Hong Kong Stock Exchange that the group's self-developed tyrosine kinase 2 selective allosteric inhibitor HS-10374 has reached common major endpoints in critical phase III clinical trials for moderate to severe plaque psoriasis in adults.